Response of Human Epidermal Growth Factor Receptor 2-Expressing Prostate Cancer to Trastuzumab Deruxtecan

被引：0
作者：
Lap, Coen J. [1 ,2 ]
Rajendran, Rithika [1 ,2 ]
Martin, Jose Manuel [1 ,2 ]
Uppal, Manisha [3 ]
Escobar, Asha [1 ,2 ]
Heiraty, Angela M.
Estephan, Fayez [1 ,2 ,3 ]
Hahn, Winnie [1 ,2 ]
Subrahmanyam, Ramesh [1 ,2 ]
Nava, Victor E. [1 ,2 ]
Jain, Maneesh [1 ,2 ]
机构：
[1] Georgetown Univ, Washington DC VA Med Ctr, Edward P Evans Precis Oncol Ctr Excellence, Washington, DC 20007 USA
[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
[3] George Washington Univ, Sch Med, Washington, DC USA
来源：
ANNALS OF INTERNAL MEDICINE | 2024年 / 177卷 / 12期
关键词：
D O I：
10.7326/ANNALS-24-01409
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1738 / 1741
页数：4
相关论文
共 5 条
  • [1] Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
    Curigliano, Giuseppe
    Hu, Xichun
    Dent, Rebecca Alexandra
    Yonemori, Kan
    Barrios Sr, Carlos H.
    O'Shaughnessy, Joyce
    Wildiers, Hans
    Zhang, Qingyuan
    Im, Seock-Ah
    Saura, Cristina
    Biganzoli, Laura
    Sohn, Joohyuk
    Levy, Christelle
    Jacot, William
    Begbie, Natasha
    Ke, Jun
    Patel, Gargi Surendra
    Bardia, Aditya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA1000 - LBA1000
  • [2] The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma
    Estephan, Fayez
    Banagan, Jeff
    Antonio, Martha
    Liu, Shanshan
    Diao, Guoqing
    Rozalen, Alexandra Zara
    Rajendran, Rithika
    Krasnow, Steven
    Subrahmanyam, Ramesh
    Nava, Victor E.
    Jain, Maneesh
    [J]. ANNALS OF DIAGNOSTIC PATHOLOGY, 2023, 67
  • [3] The mutational landscape of lethal castration-resistant prostate cancer
    Grasso, Catherine S.
    Wu, Yi-Mi
    Robinson, Dan R.
    Cao, Xuhong
    Dhanasekaran, Saravana M.
    Khan, Amjad P.
    Quist, Michael J.
    Jing, Xiaojun
    Lonigro, Robert J.
    Brenner, J. Chad
    Asangani, Irfan A.
    Ateeq, Bushra
    Chun, Sang Y.
    Siddiqui, Javed
    Sam, Lee
    Anstett, Matt
    Mehra, Rohit
    Prensner, John R.
    Palanisamy, Nallasivam
    Ryslik, Gregory A.
    Vandin, Fabio
    Raphael, Benjamin J.
    Kunju, Lakshmi P.
    Rhodes, Daniel R.
    Pienta, Kenneth J.
    Chinnaiyan, Arul M.
    Tomlins, Scott A.
    [J]. NATURE, 2012, 487 (7406) : 239 - 243
  • [4] Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
    Meric-Bernstam, Funda
    Makker, Vicky
    Oaknin, Ana
    Oh, Do-Youn
    Banerjee, Susana
    Gonzalez-Martin, Antonio
    Jung, Kyung Hae
    Lugowska, Iwona
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Fielding, Anitra
    Ma, Yan
    Puvvada, Soham
    Shire, Norah
    Lee, Jung-Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 47 - +
  • [5] Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer
    Minner, Sarah
    Jessen, Birte
    Stiedenroth, Lars
    Burandt, Eike
    Koellermann, Jens
    Mirlacher, Martina
    Erbersdobler, Andreas
    Eichelberg, Christian
    Fisch, Margit
    Bruemmendorf, Tim Henrik
    Bokemeyer, Carsten
    Simon, Ronald
    Steuber, Thomas
    Graefen, Markus
    Huland, Hartwig
    Sauter, Guido
    Schlomm, Thorsten
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (05) : 1553 - 1560
1